U.S. COMPANY FILING
JOHNSON & JOHNSON — Form 10-K filed 2026-02-11
Filing text preview
Johnson & Johnson reported FY2025 sales of $94.2 billion, up 6.0%, with net earnings of $26.8 billion and operating cash flow of $24.5 billion. The company completed the Intra-Cellular Therapies acquisition, issued $9.2 billion in debt, and announced plans to separate its Orthopaedics business. Dividend increased for the 63rd consecutive year. Risks include litigation, restructuring, and macroeconomic factors.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record